Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Non-allogeneic immunotherapy in acute myeloid leukaemia.

Adès L, Sébert M, Fenaux P.

Lancet Haematol. 2019 Aug 7. pii: S2352-3026(19)30159-0. doi: 10.1016/S2352-3026(19)30159-0. [Epub ahead of print] No abstract available.

PMID:
31400960
2.

Guadecitabine in myelodysplastic syndromes: promising but there is still progress to be made.

Adès L, Sebert M, Fenaux P.

Lancet Haematol. 2019 Jun;6(6):e290-e291. doi: 10.1016/S2352-3026(19)30079-1. Epub 2019 May 3. No abstract available.

PMID:
31060978
3.

Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum.

Sarasin A, Quentin S, Droin N, Sahbatou M, Saada V, Auger N, Boursin Y, Dessen P, Raimbault A, Asnafi V, Schmutz JL, Taïeb A, Menck CFM, Rosselli F, La Rochelle LD, Robert C, Sicre de Fontbrune F, Sébert M, Leblanc T, Kannouche P, De Botton S, Solary E, Soulier J.

Blood. 2019 Jun 20;133(25):2718-2724. doi: 10.1182/blood-2019-01-895698. Epub 2019 Mar 26. No abstract available.

4.

Risk Factors for Wound Infections after Deformity Correction Surgery in Neuromuscular Scoliosis.

Janjua MB, Toll B, Ghandi S, Sebert ME, Swift DM, Pahys JM, Samdani AF, Hwang SW.

Pediatr Neurosurg. 2019;54(2):108-115. doi: 10.1159/000496693. Epub 2019 Feb 15.

PMID:
30783030
5.

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2019 Aug;104(8):1565-1571. doi: 10.3324/haematol.2018.207118. Epub 2019 Feb 7.

6.

A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).

Ades L, Guerci-Bresler A, Cony-Makhoul P, Legros L, Sebert M, Braun T, Delaunay J, Desseaux K, Chevret S, Fenaux P.

Haematologica. 2019 Apr;104(4):e131-e133. doi: 10.3324/haematol.2018.203885. Epub 2018 Oct 31. No abstract available.

7.

Thrombin modifies growth, proliferation and apoptosis of human colon organoids: a protease-activated receptor 1- and protease-activated receptor 4-dependent mechanism.

Sébert M, Denadai-Souza A, Quaranta M, Racaud-Sultan C, Chabot S, Lluel P, Monjotin N, Alric L, Portier G, Kirzin S, Bonnet D, Ferrand A, Vergnolle N.

Br J Pharmacol. 2018 Sep;175(18):3656-3668. doi: 10.1111/bph.14430. Epub 2018 Aug 7.

8.

A landscape of germ line mutations in a cohort of inherited bone marrow failure patients.

Bluteau O, Sebert M, Leblanc T, Peffault de Latour R, Quentin S, Lainey E, Hernandez L, Dalle JH, Sicre de Fontbrune F, Lengline E, Itzykson R, Clappier E, Boissel N, Vasquez N, Da Costa M, Masliah-Planchon J, Cuccuini W, Raimbault A, De Jaegere L, Adès L, Fenaux P, Maury S, Schmitt C, Muller M, Domenech C, Blin N, Bruno B, Pellier I, Hunault M, Blanche S, Petit A, Leverger G, Michel G, Bertrand Y, Baruchel A, Socié G, Soulier J.

Blood. 2018 Feb 15;131(7):717-732. doi: 10.1182/blood-2017-09-806489. Epub 2017 Nov 16.

9.

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.

Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L.

Leuk Res. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27.

PMID:
29112938
10.

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R.

Blood Cancer J. 2017 May 12;7(5):e562. doi: 10.1038/bcj.2017.41. No abstract available.

11.

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.

Ades L, Prebet T, Stamatoullas A, Recher C, Guieze R, Raffoux E, Bouabdallah K, Hunault M, Wattel E, Stalnikiewicz L, Toma A, Dombret H, Vey N, Sebert M, Gardin C, Chaffaut C, Chevret S, Fenaux P.

Haematologica. 2017 Apr;102(4):728-735. doi: 10.3324/haematol.2016.151894. Epub 2016 Dec 29.

12.

Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?

Bigenwald C, Harel S, Chevignon F, Roos-Weil D, Bernard OA, Amorim S, Brice P, Adès L, Nloga AM, Sébert M, Braun T, Eclache V, Thieblemont C, Fenaux P.

Br J Haematol. 2018 Jan;180(2):304-308. doi: 10.1111/bjh.14323. Epub 2016 Sep 23. No abstract available.

PMID:
27662562
13.

Efficacy of eculizumab against Eosinophilic Fasciitis associated with Paroxysmal Nocturnal Haemoglobinuria.

Frumholtz L, Sebert M, de Masson A, Attias P, Ades L, Roux J, Jachiet M, Cabannes-Hamy A, Elena Noguera M, Attencourt C, Bagot M, Socié G, Rybojad M, de La Tour RP, Bouaziz JD.

J Eur Acad Dermatol Venereol. 2017 Feb;31(2):e101-e102. doi: 10.1111/jdv.13819. Epub 2016 Jul 12. No abstract available.

PMID:
27401544
14.

Low Utility of Pediatric Isolator Blood Culture System for Detection of Fungemia in Children: a 10-Year Review.

Campigotto A, Richardson SE, Sebert M, McElvania TeKippe E, Chakravarty A, Doern CD.

J Clin Microbiol. 2016 Sep;54(9):2284-7. doi: 10.1128/JCM.00578-16. Epub 2016 Jun 15.

15.

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.

Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry.

Br J Haematol. 2016 Dec;175(5):975-979. doi: 10.1111/bjh.13902. Epub 2016 Jan 15. No abstract available.

PMID:
26773632
16.

Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.

Wanquet A, Prebet T, Berthon C, Sebert M, Roux C, Kulasekararaj A, Micol JB, Esterni B, Itzykson R, Thepot S, Recher C, Delaunay J, Dreyfus F, Mufti G, Fenaux P, Vey N.

Am J Hematol. 2015 Oct;90(10):859-63. doi: 10.1002/ajh.24099. Epub 2015 Jul 14.

17.

Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.

Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti AM, Sebert M, Boissel N, Robin M, Vey N, Kiladjian JJ, Dombret H, Cluzeau T.

Br J Haematol. 2016 Feb;172(4):628-30. doi: 10.1111/bjh.13516. Epub 2015 Jun 10. No abstract available.

PMID:
26061174
18.

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.

Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).

Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7.

PMID:
25449687
19.

Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML.

Sébert M, Porcher R, Robin M, Adès L, Boissel N, Raffoux E, Xhaard A, Dhedin N, Larghero J, Himberlin C, Delmer A, Fenaux P, Dombret H, Socié G, de Latour RP.

Bone Marrow Transplant. 2015 Jan;50(1):74-81. doi: 10.1038/bmt.2014.199. Epub 2014 Sep 22.

PMID:
25243624
20.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P.

Leuk Res. 2014 Jul;38(7):751-5. doi: 10.1016/j.leukres.2014.03.012. Epub 2014 Mar 23.

PMID:
24836762
21.

Competence in Streptococcus pneumoniae is a response to an increasing mutational burden.

Gagne AL, Stevens KE, Cassone M, Pujari A, Abiola OE, Chang DJ, Sebert ME.

PLoS One. 2013 Aug 13;8(8):e72613. doi: 10.1371/journal.pone.0072613. eCollection 2013.

22.

TSH restores a summer phenotype in photoinhibited mammals via the RF-amides RFRP3 and kisspeptin.

Klosen P, Sébert ME, Rasri K, Laran-Chich MP, Simonneaux V.

FASEB J. 2013 Jul;27(7):2677-86. doi: 10.1096/fj.13-229559. Epub 2013 Mar 28.

PMID:
23538709
23.
24.

[Diagnosis of sleep disordered breathing using portable methods].

Penzel T, Blau A, Garcia C, Schöbel C, Sebert M, Baumann G, Fietze I.

Pneumologie. 2013 Feb;67(2):112-7. doi: 10.1055/s-0032-1325943. Epub 2012 Dec 17. German.

25.

Erlotinib antagonizes ABC transporters in acute myeloid leukemia.

Lainey E, Sébert M, Thépot S, Scoazec M, Bouteloup C, Leroy C, De Botton S, Galluzzi L, Fenaux P, Kroemer G.

Cell Cycle. 2012 Nov 1;11(21):4079-92. doi: 10.4161/cc.22382. Epub 2012 Oct 24.

26.

The HtrA protease from Streptococcus pneumoniae digests both denatured proteins and the competence-stimulating peptide.

Cassone M, Gagne AL, Spruce LA, Seeholzer SH, Sebert ME.

J Biol Chem. 2012 Nov 9;287(46):38449-59. doi: 10.1074/jbc.M112.391482. Epub 2012 Sep 25.

27.

Stimulatory effect of RFRP-3 on the gonadotrophic axis in the male Syrian hamster: the exception proves the rule.

Ancel C, Bentsen AH, Sébert ME, Tena-Sempere M, Mikkelsen JD, Simonneaux V.

Endocrinology. 2012 Mar;153(3):1352-63. doi: 10.1210/en.2011-1622. Epub 2012 Jan 24.

PMID:
22275511
28.

Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.

Tailler M, Senovilla L, Lainey E, Thépot S, Métivier D, Sébert M, Baud V, Billot K, Fenaux P, Galluzzi L, Boehrer S, Kroemer G, Kepp O.

Oncogene. 2012 Jul 26;31(30):3536-46. doi: 10.1038/onc.2011.521. Epub 2011 Nov 21.

PMID:
22105358
29.

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.

Adès L, Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Eclache V, Delaunay J, Bouscary D, Visanica S, Turlure P, Bresler AG, Cabrol MP, Banos A, Blanc M, Vey N, Delmer A, Wattel E, Chevret S, Fenaux P.

Haematologica. 2012 Feb;97(2):213-8. doi: 10.3324/haematol.2011.045914. Epub 2011 Oct 11.

30.

Competence in Streptococcus pneumoniae is regulated by the rate of ribosomal decoding errors.

Stevens KE, Chang D, Zwack EE, Sebert ME.

MBio. 2011 Sep 20;2(5). pii: e00071-11. doi: 10.1128/mBio.00071-11. Print 2011.

31.

Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.

Boehrer S, Galluzzi L, Lainey E, Bouteloup C, Tailler M, Harper F, Pierron G, Adès L, Thépot S, Sébert M, Gardin C, de Botton S, Fenaux P, Kroemer G.

Cell Cycle. 2011 Sep 15;10(18):3168-75. Epub 2011 Sep 15.

PMID:
21897118
32.

Frequent beneficial mutations during single-colony serial transfer of Streptococcus pneumoniae.

Stevens KE, Sebert ME.

PLoS Genet. 2011 Aug;7(8):e1002232. doi: 10.1371/journal.pgen.1002232. Epub 2011 Aug 18.

33.

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L.

Leuk Res. 2011 Nov;35(11):1444-8. doi: 10.1016/j.leukres.2011.05.034. Epub 2011 Jun 28.

PMID:
21715006
34.

Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action.

Lainey E, Thépot S, Bouteloup C, Sébert M, Adès L, Tailler M, Gardin C, de Botton S, Baruchel A, Fenaux P, Kroemer G, Boehrer S.

Biochem Pharmacol. 2011 Nov 15;82(10):1457-66. doi: 10.1016/j.bcp.2011.05.011. Epub 2011 Jun 1.

PMID:
21664897
35.

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.

Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S.

Cell Cycle. 2011 Jul 15;10(14):2323-30. Epub 2011 Jul 15.

PMID:
21654193
36.

Neuroendocrine control by dopamine of teleost reproduction.

Dufour S, Sebert ME, Weltzien FA, Rousseau K, Pasqualini C.

J Fish Biol. 2010 Jan;76(1):129-60. doi: 10.1111/j.1095-8649.2009.02499.x. Review.

PMID:
20738703
37.

Insights into the mechanism by which kisspeptin stimulates a preovulatory LH surge and ovulation in seasonally acyclic ewes: potential role of estradiol.

Sébert ME, Lomet D, Saïd SB, Monget P, Briant C, Scaramuzzi RJ, Caraty A.

Domest Anim Endocrinol. 2010 May;38(4):289-98. doi: 10.1016/j.domaniend.2010.01.001. Epub 2010 Jan 16.

PMID:
20097511
38.

Revised recommendations for computer-based sleep recording and analysis.

Penzel T, Glos M, Schobel C, Sebert M, Diecker B, Fietze I.

Conf Proc IEEE Eng Med Biol Soc. 2009;2009:7099-101. doi: 10.1109/IEMBS.2009.5332903.

PMID:
19963944
39.

Treatment for metastatic malignant melanoma: old drugs and new strategies.

Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D.

Crit Rev Oncol Hematol. 2010 Apr;74(1):27-39. doi: 10.1016/j.critrevonc.2009.08.005. Epub 2009 Sep 24. Review.

PMID:
19781957
40.

Bacteriocin activity of Streptococcus pneumoniae is controlled by the serine protease HtrA via posttranscriptional regulation.

Dawid S, Sebert ME, Weiser JN.

J Bacteriol. 2009 Mar;191(5):1509-18. doi: 10.1128/JB.01213-08. Epub 2008 Dec 19.

41.

Melatonin activates brain dopaminergic systems in the eel with an inhibitory impact on reproductive function.

Sébert ME, Legros C, Weltzien FA, Malpaux B, Chemineau P, Dufour S.

J Neuroendocrinol. 2008 Jul;20(7):917-29. doi: 10.1111/j.1365-2826.2008.01744.x. Epub 2008 Apr 28.

PMID:
18445127
42.

The Streptococcus pneumoniae competence regulatory system influences respiratory tract colonization.

Kowalko JE, Sebert ME.

Infect Immun. 2008 Jul;76(7):3131-40. doi: 10.1128/IAI.01696-07. Epub 2008 Apr 28.

43.

Effects of high hydrostatic pressure on the pituitary-gonad axis in the European eel, Anguilla anguilla (L.).

Sébert ME, Amérand A, Vettier A, Weltzien FA, Pasqualini C, Sébert P, Dufour S.

Gen Comp Endocrinol. 2007 Aug-Sep;153(1-3):289-98. Epub 2007 Jan 25.

PMID:
17324430
44.

Androgen-dependent stimulation of brain dopaminergic systems in the female European eel (Anguilla anguilla).

Weltzien FA, Pasqualini C, Sébert ME, Vidal B, Le Belle N, Kah O, Vernier P, Dufour S.

Endocrinology. 2006 Jun;147(6):2964-73. Epub 2006 Mar 16.

45.

Pneumococcal HtrA protease mediates inhibition of competence by the CiaRH two-component signaling system.

Sebert ME, Patel KP, Plotnick M, Weiser JN.

J Bacteriol. 2005 Jun;187(12):3969-79.

46.

Dopaminergic inhibition of reproduction in teleost fishes: ecophysiological and evolutionary implications.

Dufour S, Weltzien FA, Sebert ME, Le Belle N, Vidal B, Vernier P, Pasqualini C.

Ann N Y Acad Sci. 2005 Apr;1040:9-21. Review.

PMID:
15891002
47.

Severe influenza B myocarditis and myositis.

Tabbutt S, Leonard M, Godinez RI, Sebert M, Cullen J, Spray TL, Friedman D.

Pediatr Crit Care Med. 2004 Jul;5(4):403-6.

PMID:
15215016
48.

An outbreak of Serratia marcescens bacteremia after general anesthesia.

Sebert ME, Manning ML, McGowan KL, Alpern ER, Bell LM.

Infect Control Hosp Epidemiol. 2002 Dec;23(12):733-9.

PMID:
12517016

Supplemental Content

Loading ...
Support Center